Roche registers giredestrant Phase 3 trial; six other studies update
Weekly roundup: a new giredestrant trial lists as recruiting ahead of its 2026 start, while six other Roche-linked studies post status changes.
This week's registry activity centers on a newly posted Phase 3 giredestrant trial, alongside six other updates spanning completions and new listings.
- A Phase IIIb trial called "kalitERA" is testing giredestrant in patients with estrogen receptor-positive, HER2-negative early breast cancer, sponsored by Hoffmann-La Roche.1 The study is listed with an overall status of recruiting, though its start date is estimated for 2026-12-11, and planned enrollment is 1500 participants.1
- A Phase IV study of the Port Delivery System with ranibizumab in neovascular age-related macular degeneration, sponsored by Genentech, Inc.2, is listed as active, not recruiting, with an estimated enrollment of 188 participants.2
- A Phase II trial of tobemstomig combined with axitinib, with or without tiragolumab, compared against pembrolizumab plus axitinib in previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma, sponsored by Hoffmann-La Roche3, is listed as completed, with actual enrollment of 199 participants.3
- A Phase II trial comparing tobemstomig plus nab-paclitaxel against pembrolizumab plus nab-paclitaxel in previously untreated, PD-L1-positive triple-negative breast cancer, sponsored by Hoffmann-La Roche4, is also completed, with 83 participants enrolled.4
- A Phase Ib/II trial of glofitamab and atezolizumab or polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin's lymphoma, sponsored by Hoffmann-La Roche5, is listed as completed, with 211 participants enrolled.5
- The "PAcMan" trial testing polatuzumab vedotin, mosunetuzumab, and acalabrutinib in previously untreated mantle cell lymphoma6 is listed as not yet recruiting, sponsored by University of Washington with Genentech, Inc. as a collaborator,6 with planned enrollment of 27 participants.6
- A diagnostic study evaluating ctDNA tumor fraction for detection of ESR1 mutations in HR-positive, HER2-negative metastatic breast cancer7 is listed as not yet recruiting, sponsored by Yale University with Foundation Medicine as a collaborator,7 with estimated enrollment of 155 participants.7
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.